Zacks Research Has Bearish Forecast for PAHC Q1 Earnings

Phibro Animal Health Co. (NASDAQ:PAHC) – Investment analysts at Zacks Research dropped their Q1 2026 earnings per share estimates for Phibro Animal Health in a research report issued to clients and investors on Thursday, November 28th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $0.31 for the quarter, down from their prior forecast of $0.32. The consensus estimate for Phibro Animal Health’s current full-year earnings is $1.61 per share. Zacks Research also issued estimates for Phibro Animal Health’s Q2 2026 earnings at $0.47 EPS, Q4 2026 earnings at $0.49 EPS and FY2026 earnings at $1.60 EPS.

A number of other research firms have also recently weighed in on PAHC. StockNews.com raised shares of Phibro Animal Health from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 28th. Barclays lifted their price target on shares of Phibro Animal Health from $13.00 to $20.00 and gave the stock an “underweight” rating in a research note on Tuesday, November 12th. JPMorgan Chase & Co. initiated coverage on shares of Phibro Animal Health in a research note on Tuesday, September 10th. They issued a “neutral” rating and a $22.00 price objective for the company. Finally, Bank of America lifted their target price on Phibro Animal Health from $13.00 to $15.00 and gave the stock an “underperform” rating in a research report on Friday, August 30th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Phibro Animal Health presently has a consensus rating of “Hold” and an average target price of $16.50.

Phibro Animal Health Trading Up 0.7 %

PAHC opened at $23.54 on Monday. The business’s 50-day simple moving average is $23.35 and its 200-day simple moving average is $20.27. The company has a market cap of $953.37 million, a P/E ratio of 54.75, a PEG ratio of 0.60 and a beta of 0.51. Phibro Animal Health has a one year low of $9.94 and a one year high of $25.98. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.69 and a current ratio of 3.23.

Phibro Animal Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 18th. Stockholders of record on Wednesday, November 27th will be issued a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, November 27th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 2.04%. Phibro Animal Health’s payout ratio is 111.63%.

Insider Transactions at Phibro Animal Health

In related news, Director E Thomas Corcoran purchased 5,000 shares of the business’s stock in a transaction dated Wednesday, September 4th. The stock was acquired at an average price of $20.02 per share, for a total transaction of $100,100.00. Following the completion of the purchase, the director now directly owns 25,000 shares of the company’s stock, valued at $500,500. This trade represents a 25.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 50.07% of the company’s stock.

Hedge Funds Weigh In On Phibro Animal Health

Institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets boosted its holdings in shares of Phibro Animal Health by 3.1% in the third quarter. BNP Paribas Financial Markets now owns 24,336 shares of the company’s stock valued at $548,000 after acquiring an additional 729 shares in the last quarter. CWM LLC lifted its holdings in shares of Phibro Animal Health by 89.8% in the 2nd quarter. CWM LLC now owns 2,188 shares of the company’s stock valued at $37,000 after buying an additional 1,035 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Phibro Animal Health by 7.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 15,393 shares of the company’s stock valued at $200,000 after buying an additional 1,063 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in Phibro Animal Health by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,912 shares of the company’s stock worth $88,000 after acquiring an additional 1,522 shares in the last quarter. Finally, Cardinal Capital Management lifted its holdings in Phibro Animal Health by 4.7% in the second quarter. Cardinal Capital Management now owns 56,027 shares of the company’s stock valued at $940,000 after acquiring an additional 2,520 shares during the period. 99.34% of the stock is owned by institutional investors and hedge funds.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.